RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-8.53%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$3.75B
AUM Growth
+$3.75B
(-18%)
Cap. Flow
-$57.3M
Cap. Flow
% of AUM
-1.53%
Top 10 Holdings %
Top 10 Hldgs %
47.18%
Holding
110
New
14
Increased
9
Reduced
11
Closed
22
Top Buys
| 1 |
Veru
VERU
|
$89.3M |
| 2 |
PepGen
PEPG
|
$80.7M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$45.5M |
| 4 |
Aclaris Therapeutics
ACRS
|
$36M |
| 5 |
Wave Life Sciences
WVE
|
$30.6M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$60.4M |
| 2 |
MacroGenics
MGNX
|
$53.8M |
| 3 |
Novavax
NVAX
|
$51M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$32.1M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$29M |
Sector Composition
| 1 | Healthcare | 98.19% |
| 2 | Financials | 1.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
TScan Therapeutics
TCRX
$106M
| – | – |
-1,021,764
| Closed | -$2.86M |
|
102
scPharmaceuticals
SCPH
$296M
| – | – |
-2,658,583
| Closed | -$15.1M |
|
|
103
Novavax
NVAX
$1.2B
| – | – |
-692,794
| Closed | -$51M |
|
|
104
MacroGenics
MGNX
$121M
| – | – |
-6,103,594
| Closed | -$53.8M |
|
105
KalVista Pharmaceuticals
KALV
$713M
| – | – |
-1,930,322
| Closed | -$28.5M |
|
106
KALA BIO
KALA
$105M
| – | – |
-10,874,613
| Closed | -$15M |
|
107
Edgewise Therapeutics
EWTX
$1.54B
| – | – |
-2,613,623
| Closed | -$25.4M |
|
|
CNTA
108
Centessa Pharmaceuticals
CNTA
$2.13B
| – | – |
-3,577,094
| Closed | -$32.1M |
|
109
Compass Therapeutics
CMPX
$466M
| – | – |
-532,958
| Closed | -$730K |
|
110
Cullinan Oncology
CGEM
$456M
| – | – |
-350,000
| Closed | -$3.67M |
|